Shares of Illumina ILMN were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were down 47.15% over the past year to $1.02, which beat the estimate of $0.77.
Revenue of $794,000,000 decreased by 12.46% from the same period last year, which beat the estimate of $715,910,000.
Guidance
Illumina hasn't issued any earnings guidance for the time being.
Illumina hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Oct 29, 2020
Time: 05:00 PM
Technicals
Company's 52-week high was at $404.20
52-week low: $196.78
Price action over last quarter: down 12.56%
Company Description
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 17% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
